New weight‑loss pill cleared by FDA
Eli Lilly’s newly approved oral weight‑loss pill — billed as a first‑of‑its‑kind entrant in the market — has won FDA approval and is now being offered as demand for obesity treatments surges. (Industry coverage frames it as a milestone in the expanding medical toolbox for obesity, arriving as GLP‑1s and other approaches reshape care.) (thestreet.com)
Weight-loss drugs work by making the body act like it just ate. A gut hormone called glucagon-like peptide-1 tells the brain “you’re full,” slows the stomach, and cuts hunger, which is why these medicines can lower both weight and blood sugar. (jamanetwork.com) Most of the big new obesity drugs have been shots because they are built from fragile protein-like molecules that are hard to get through the stomach. Eli Lilly’s new drug, Foundayo, uses a small-molecule version of that same signal, which lets it be made as a once-daily tablet. (nejm.org, medical.lilly.com) The Food and Drug Administration approved Foundayo, whose generic name is orforglipron, on April 1, 2026. The approval covers adults with obesity, or adults who are overweight and also have at least one weight-related medical problem, alongside diet and exercise. (fda.gov, medical.lilly.com) Lilly says the pill can be taken at any time of day without food or water restrictions. That is a practical difference from earlier oral glucagon-like peptide-1 drugs, which often came with strict timing rules that made them feel more like a ritual than a pill. (prnewswire.com, time.com) In Lilly’s 72-week ATTAIN-1 trial, people on the highest dose lost an average of 12.4% of their body weight, or about 27.3 pounds, versus 0.9% on placebo. In the published study, lower doses also beat placebo, with average losses ranging from 7.5% to 11.2%. (nejm.org, prnewswire.com) The side effects looked familiar to anyone who has followed this drug class. The most common problems were stomach-related, including nausea, vomiting, diarrhea, and constipation, and most were mild to moderate, though discontinuation rates were higher than placebo. (nejm.org) The label also carries the same boxed warning seen on this family of medicines about thyroid C-cell tumors in rodents. The prescribing information says Foundayo should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (pi.lilly.com) This approval lands in a market that has been dominated by injectable brands like Wegovy and Zepbound. Doctors and patients have wanted pills because some people avoid needles, some stop treatment when injections are inconvenient, and demand for obesity treatment has outgrown the old idea that one format fits everyone. (jamanetwork.com, jamanetwork.com) Lilly says prescriptions are being accepted immediately through LillyDirect, with shipping that began April 6, 2026. The company says the starting price is $25 a month for commercially insured patients with coverage and $149 for self-pay through its direct program. (prnewswire.com, drugs.com) The bigger shift is that obesity treatment is starting to look more like blood-pressure treatment, with multiple drug types and multiple formats instead of one blockbuster shot. Foundayo does not replace injections, but it gives doctors a new option for people who want glucagon-like peptide-1 treatment in the form most patients already know how to take: a pill. (jamanetwork.com, thelancet.com)
